United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary CRYOLIFE AND ENDOLOGIX SIGN DEVELOPMENT AGREEMENT FOR BIOFOAM
Endologix to develop CryoLife’s innovative, self-expanding sealant as a filling agent for aortic aneurysms
View HTML
Toggle Summary ENDOLOGIX REPORTS THIRD QUARTER RESULTS
ENDOLOGIX REPORTS THIRD QUARTER RESULTS Irvine, Calif. (November 9, 2004) Endologix, Inc., (NASDAQ: ELGX) today announced financial results for the quarter ended September 30, 2004. “We are exceptionally pleased to receive conditional U.S. marketing approval for our Powerlink® System
View HTML
Toggle Summary Endologix Announces Special Meeting of Stockholders
Endologix Announces Special Meeting of Stockholders IRVINE, Calif. (November 1, 2004) Endologix, Inc. (Nasdaq: ELGX) today announced that it will hold a special meeting of stockholders on January 11, 2005 for the purpose of approving a 2,000,000 share increase in authorized shares under its 1996
View HTML
Toggle Summary ENDOLOGIX RECEIVES FDA CONDITIONAL APPROVAL LETTER FOR Powerlink SYSTEM
- Company to Initiate Focused U.S. Market Launch -
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES TCT 2004 EVENTS
Live Powerlink System Surgical Procedure and Favorable Follow-on Clinical Data Presented
View HTML
Toggle Summary ENDOLOGIX NAMES ROBERT J. KRIST CHIEF FINANCIAL OFFICER
ENDOLOGIX NAMES ROBERT J. KRIST CHIEF FINANCIAL OFFICER IRVINE, Calif. (August 11, 2004) - Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that Robert J.
View HTML
Toggle Summary ENDOLOGIX TO PRESENT AT PACIFIC GROWTH EQUITIES LIFE SCIENCES GROWTH CONFERENCE
Webcast Scheduled June 9 at 5:00 p.m. ET
View HTML
Toggle Summary ENDOLOGIX, INC. REPORTS 2004 FIRST QUARTER RESULTS
ENDOLOGIX, INC. REPORTS 2004 FIRST QUARTER RESULTS Irvine, Calif. – May 10, 2004 – Endologix, Inc., (Nasdaq: ELGX), developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment for abdominal aortic aneurysms (AAAs), today
View HTML
Toggle Summary ENDOLOGIX PROVIDES DETAILS OF Powerlink® SYSTEM PIVOTAL TRIAL AT ANNUAL MEETING OF THE EASTERN VASCULAR SOCIETY
97.9% Device Deployment Success, 31% Treated with Regional or Local Anesthesia
View HTML
Toggle Summary ENDOLOGIX UPDATE ON U.S. REGULATORY PROGRESS
ENDOLOGIX UPDATE ON U.S. REGULATORY PROGRESS Reaffirms expectations for FDA approval in the second half of 2004 IRVINE, Calif. (May 4, 2004) – Endologix, Inc. (Nasdaq: ELGX) today provided an update on its recent communication with the FDA concerning its pending PMA Application for its
View HTML
Toggle Summary Endologix Completes $16.3 Million Private Placement
Endologix Completes $16.3 Million Private Placement Irvine, Calif. – March 10, 2004 – Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced the completion of a previously announced
View HTML
Toggle Summary ENDOLOGIX, INC. REPORTS 2003 FOURTH QUARTER AND YEAR END RESULTS
ENDOLOGIX, INC. REPORTS 2003 FOURTH QUARTER AND YEAR END RESULTS Irvine, Calif. – March 10, 2004 – Endologix, Inc., (Nasdaq: ELGX), developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment for abdominal aortic aneurysms (AAAs),
View HTML
Toggle Summary Endologix Announces $16.3 Million Private Placement
Endologix Announces $16.3 Million Private Placement Irvine, Calif. – March 8, 2004 – Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that it has signed definitive agreements to
View HTML
Toggle Summary FOUR-YEAR ITALIAN COMPARATIVE STUDY SUPPORTS ENDOLOGIX Powerlink SINGLE-PIECE DESIGN
FOUR-YEAR ITALIAN COMPARATIVE STUDY SUPPORTS ENDOLOGIX Powerlink SINGLE-PIECE DESIGN Study Data to be Presented at the International Congress Conference Irvine, Calif. - February 11, 2004 - Endologix, Inc. (Nasdaq: ELGX) today announced that data from a four-year retrospective comparative Italian
View HTML
Toggle Summary ENDOLOGIX TO HOST CONFERENCE CALL TO DISCUSS DEVELOPMENT AGREEMENT FOR BIOFOAM
ENDOLOGIX TO HOST CONFERENCE CALL TO DISCUSS DEVELOPMENT AGREEMENT FOR BIOFOAM IRVINE, Calif. (January 10, 2004) - Endologix, Inc. (Nasdaq: ELGX) will host a conference call tomorrow, Tuesday, January 11, 2005 at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) to discuss the details of its
View HTML